Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17591785 | 1.00 | SMYD3 (0.72) | SMYD3GAAKMT2AMEN1PARP1 | |
| SCHEMBL17591784 | 1.00 | SMYD3 (0.72) | SMYD3GAAKMT2AMEN1PARP1 | |
| SCHEMBL23575999 | 0.83 | SMYD3 (1.00) | SMYD3GAAKMT2AMEN1 | |
| SCHEMBL19710411 | 0.83 | SMYD3 (1.00) | SMYD3GAAKMT2AMEN1 | |
| SCHEMBL17591721 | 0.83 | SMYD3 (0.67) | SMYD3GAAKMT2AMEN1PARP1 | |
| SCHEMBL17591722 | 0.83 | SMYD3 (0.67) | SMYD3GAAKMT2AMEN1PARP1 | |
| SCHEMBL28811313 | 0.83 | SMYD3 (0.67) | SMYD3GAAKMT2AMEN1PARP1 | |
| SCHEMBL21489773 | 0.79 | SMYD3 (1.00) | SMYD3GAA | |
| SCHEMBL19710225 | 0.79 | SMYD3 (1.00) | SMYD3GAA | |
| SCHEMBL29779515 | 0.79 | SMYD3 (0.60) | SMYD3GAAKMT2AMEN1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028619-A | SMYD inhibitors | EPIZYME股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885GAA 1705/4885KMT2A 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.